Physician profile
Misty Bailey
NPI 1376121079
$3,288.90
in general payments reported to CMS, 2019-2025
27 companies · $916 in 2025
The $916 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $19.06 · 2022: $466 · 2023: $777 · 2024: $1,111 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,616 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,615.50 |
| Education | $187.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $696.40 | 2022-2025 | |
| Pfizer INC. | $337.86 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.30 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $248.64 | 2022-2024 | Farxiga, Atacand, Brilinta |
| Jazz Pharmaceuticals INC. | $243.89 | 2024-2025 | |
| Amgen INC. | $238.94 | 2023-2025 | Repatha, Repatha |
| Novo Nordisk INC | $184.46 | 2024-2025 | Wegovy, Ozempic |
| Boston Scientific Corporation | $154.73 | 2022-2025 | Watchman Flx, Watchman Access System |
| Janssen Pharmaceuticals, INC | $127.47 | 2022-2024 | Xarelto |
| Neurelis, INC. | $105.07 | 2024 | Valtoco |
| Abbvie INC. | $101.80 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.75 | 2023-2025 | Lifevest |
| Edwards Lifesciences Corporation | $91.83 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $51.80 | 2023-2024 | Eliquis, Camzyos |
| Harmony Biosciences LLC | $50.90 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $47.70 | 2025 | Rexulti |
| Avadel Cns Pharmaceuticals, LLC | $38.49 | 2024-2025 | Lumryz |
| Abiomed | $35.80 | 2025 | |
| Inspire Medical Systems, INC. | $34.12 | 2025 | Inspire |
| Biotronik INC. | $26.31 | 2022 | |
| Esperion Therapeutics, INC. | $20.20 | 2025 | Nexletol |
| W. L. Gore & Associates, INC. | $19.06 | 2021 | |
| Medline Industries LP | $18.11 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $15.39 | 2024 | |
| Axsome Therapeutics, INC. | $15.25 | 2025 | Sunosi |
| Lilly USA, LLC | $14.92 | 2025 | Zepbound |
| Cardiovascular Systems INC. | $13.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Misty Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.